Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 15/20 | 0.88 |
| ▸ | GLP1R | P43220 | 2/20 | 0.75 |
| ▸ | CCKBR | P32239 | 1/20 | 0.75 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.69 |
| ▸ | GRPR | P30550 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teriparatide SCHEMBL720581 | 0.94 | PTH1R (0.90) | PTH1RGLP1RCCKBR | |
| Teriparatide SCHEMBL29354459 | 0.94 | PTH1R (0.91) | PTH1RGLP1RCCKBR | |
| SCHEMBL28980015 | 0.94 | PTH1R (0.91) | PTH1RGLP1RCCKBR | |
| SCHEMBL1773403 | 0.92 | PTH1R (0.85) | PTH1RGLP1RCCKBR | |
| SCHEMBL29354319 | 0.90 | GLP1R (0.81) | PTH1RGLP1RCCKBRNR3C1 | |
| SCHEMBL15268863 | 0.90 | GLP1R (0.81) | PTH1RGLP1RCCKBRNR3C1 | |
| Teriparatide SCHEMBL29357752 | 0.90 | PTH1R (0.85) | PTH1RGLP1RCCKBR | |
| Hydrochloric Acid SCHEMBL29363528 | 0.90 | GLP1R (0.80) | PTH1RGLP1RCCKBRNR3C1 | |
| SCHEMBL29376455 | 0.90 | PTH1R (0.81) | PTH1RGLP1RCCKBRNR3C1 | |
| Teduglutide SCHEMBL20898050 | 0.89 | GLP1R (0.82) | PTH1RGLP1RCCKBRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118126197-A | Recombinant PTH fusion protein and construction method and application thereof | 康众(广东)生物医药有限公司 | 2024-06-04 | — | — | CN | claimed |
| US-12534511-B2 | Serum albumin-binding fibronectin type III domains | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-27 | — | — | US | disclosed |
| US-12529088-B2 | Helper factors for expressing proteins in yeast | LONZA LTD (CH) | 2026-01-20 | — | — | US | disclosed |
| EP-3833622-B1 | TRANSFER STATION FOR API SEED CRYSTALS | LONZA AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-12497624-B2 | Methods for improving production of biological products by reducing the level of endogenous protein | LONZA LTD (CH) | 2025-12-16 | — | — | US | disclosed |
| EP-4638756-A1 | HOST CELLS WITH PAT1 KNOCKOUT FOR INCREASED SPECIFIC PROTEIN PRODUCTIVITY | Lonza Ltd. (CH) | 2025-10-29 | — | — | EP | disclosed |
| EP-4608986-A1 | IMPROVED METHOD TO INCREASE DRUG SUBSTANCE YIELD | PharmaEssentia Corporation (TW) | 2025-09-03 | — | — | EP | disclosed |
| US-12404309-B2 | Host cell for producing a protein of interest | LONZA LTD (CH) | 2025-09-02 | — | — | US | disclosed |
| US-12371650-B2 | Method and system for providing buffer solutions | LONZA LTD (CH) | 2025-07-29 | — | — | US | disclosed |
| US-12352625-B2 | Automated control of cell culture using Raman spectroscopy | LONZA LTD (CH) | 2025-07-08 | — | — | US | disclosed |
| EP-3572424-B1 | SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022069613-A1 | HOST CELLS OVEREXPRESSING TRANSLATIONAL FACTORS | LONZA LTD (CH) | 2022-04-07 | — | — | WO | disclosed |
| US-20220106800-A1 | CUSTOMIZABLE FACILITY | LONZA LTD (CH) | 2022-04-07 | — | — | US | disclosed |
| EP-3874047-B1 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | LONZA AG (CH) | 2022-04-06 | — | — | EP | disclosed |
| US-11279922-B2 | Delivery of therapeutic agents by a collagen binding protein | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220049275-A1 | SSI CELLS WITH PREDICTABLE AND STABLE TRANSGENE EXPRESSION AND METHODS OF FORMATION | LONZA AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-20220042064-A1 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | LONZA LTD (CH) | 2022-02-10 | — | — | US | disclosed |
| EP-3947695-A1 | MUT- METHYLOTROPHIC YEAST | Universität für Bodenkultur Wien (AT) | 2022-02-09 | — | — | EP | disclosed |
| US-11236520-B2 | Customizable facility | LONZA LTD (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-3942014-A1 | CONTINUOUS BLADE IMPELLER | Lonza Ltd. (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534511-B2 | Serum albumin-binding fibronectin type III domains | FN1, ALB, FGB | PTH1R 3344/4885GLP1R 4287/4885CCKBR 4851/4885 |
| US-11279922-B2 | Delivery of therapeutic agents by a collagen binding protein | PTH1R, GHRHR, FGF23 | PTH1R 1/4885GLP1R 134/4885CCKBR 148/4885 |
| US-12529088-B2 | Helper factors for expressing proteins in yeast | UPF1, ILF3, YIF1A | PTH1R 2916/4885GLP1R 4828/4885CCKBR 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.